LESCOL Drug Patent Profile

When do Lescol patents expire, and when can generic versions of Lescol launch?

Lescol is a drug marketed by Novartis and Sandoz and is included in two NDAs.

The generic ingredient in LESCOL is fluvastatin sodium. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fluvastatin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lescol

A generic version of LESCOL was approved as fluvastatin sodium by MYLAN PHARMS INC on April 11^th, 2012.

Summary for LESCOL

US Patents:	0
Applicants:	2
NDAs:	2

Paragraph IV (Patent) Challenges for LESCOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LESCOL	Capsules	fluvastatin sodium	20 mg and 40 mg	020261	1	2008-06-04

US Patents and Regulatory Information for LESCOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-001	Dec 31, 1993		DISCN	Yes	No
Novartis	LESCOL	fluvastatin sodium	CAPSULE;ORAL	020261-002	Dec 31, 1993		DISCN	Yes	No
Sandoz	LESCOL XL	fluvastatin sodium	TABLET, EXTENDED RELEASE;ORAL	021192-001	Oct 6, 2000	AB	RX	Yes	Yes

International Patents for LESCOL

See the table below for patents covering LESCOL around the world.

Country	Patent Number	Title	Estimated Expiration
Czech Republic	9203633
Spain	8506622
Cyprus	1994	Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase inhibitor
Hong Kong	11191	ANALOGS OF MEVALOLACTONE AND DERIVATIVES THEREOF,PROCESSES FOR THEIR PRODUCTION,PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS

Supplementary Protection Certificates for LESCOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0114027	SPC/GB93/173	United Kingdom		SPC/GB93/173: 20031122, EXPIRES: 20080822
0114027	96C0022	Belgium		PRODUCT NAME: FLUVASTATINE SODIQUE; NAT. REGISTRATION NO/DATE: 151 IS 207 F 4 19960409; FIRST REGISTRATION: GB 0101/0360 19930823

LESCOL Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Current Status of LESCOL Patent and Market Position?

LESCOL, the brand name for a statin medication primarily used to reduce cholesterol levels, is known generically as fluvastatin. It was originally developed by Novartis and later acquired by several generic manufacturers as patent protections expired.

As of 2023, the patent protection for brand-name LESCOL (original formulation) has expired worldwide. Multiple generic versions of fluvastatin are approved, reducing market exclusivity and potentially impacting profit margins for branded formulations.

The global statin market was valued at approximately $15 billion in 2022, with predicted compound annual growth rate (CAGR) of 3.2% through 2028. The market's growth is driven by increasing prevalence of cardiovascular diseases (CVD), aging populations, and generic drug adoption.

How Strong Is the Patent and Exclusivity Landscape?

The primary patent protection for LESCOL failed in most regions by 2018, resulting in legal challenges from generic manufacturers granting broader access. Some markets may still have secondary patents or formulations in effect, but these are limited and often challengeable.

Key points:

• Patent expiration in the US was in 2018 for the original compound.
• Several European countries saw patent expiry between 2017 and 2019.
• No recent data shows active exclusivity in major markets, leading to intense generic competition.

Patent expiries diminish barriers to generic entry, pressuring branded drug prices and revenues.

What Are the Key Revenue Drivers and Market Dynamics?

Revenue generation for LESCOL depends on:

• Market penetration in developed markets: Globally, the drug faces stiff generic competition, sharply reducing margins for brand versions.
• Pricing strategies: Brands typically discount to defend market share. The presence of generics can reduce the average price by up to 80% in mature markets.
• Efficacy and safety profile: Fluvastatin has a well-established safety record, but newer statins with better lipid-lowering capabilities and fewer side effects are gaining favor.
• Regulatory landscape: Stringent safety or efficacy re-evaluations could restrict or expand access.

In the US, the number of prescriptions for fluvastatin peaked at over 3 million annually before patent expiry. Current prescriptions are primarily for generics, with pricing averaging around $0.10 per pill compared to branded prices of $1.00+.

What Are The Strategic Opportunities and Risks?

Opportunities:

• Generic market entry: High volume potential in generic form if marketed efficiently.
• Combination therapies: LESCOL can be combined with other agents for broader cardiovascular risk management.
• Export potential in emerging markets: Lower drug prices favor expansion into markets with increasing CVD prevalence and less regulatory barriers.

Risks:

• Market cannibalization: Competition from established generics limits profitability.
• Evolving treatment guidelines: Shift towards PCSK9 inhibitors or lifestyle interventions reduces statin dependency.
• Regulatory Challenges: Potential reformulations or patent disputes could delay market expansion.

What Financial Outlook Can Be Projected?

Given the generic saturation, revenue levels for LESCOL are expected to fall. Historical US sales peaked at around $300 million for branded LESCOL pre-2018. Similar declines are anticipated industry-wide.

In the generic market, margins are narrower but volume-driven. Rational pricing and economies of scale can sustain profitable operations. Expected sales revenues could decline to below $50 million annually in mature markets, but emerging markets may offer additional growth if access barriers are lowered.

What Is the Investment Perspective?

Investors should recognize the declining revenue trend caused by patent expiry, with prospects shifting toward generic sales and market expansion in developing regions. Companies with established manufacturing, distribution networks, or patents on formulations for combination therapies could unlock value.

Therapeutic competition from newer lipid-lowering agents lessens the long-term outlook for LESCOL. Smart investments focus on lifecycle management strategies, such as reformulations or new indications.

Summary of Fundamental Factors

Factor	Observation
Patent status	Expired in key jurisdictions
Market size	$15 billion global statin market (2022)
Price erosion	Up to 80% decline post-generics
Revenue trend	Declining, with peak pre-expiry (~$300M US sales)
Competition	Intense from generics and emerging therapies
Growth prospects	Limited in mature markets; potential in emerging markets

Final Analysis

LESCOL's future depends on its ability to adapt to a heavily commoditized market driven by generics. Investment considerations lean towards brands or formulations with patent protection or unique delivery mechanisms. The reduced profitability of generic fluvastatin presents limited opportunities unless coupled with strategic differentiation.

---

Key Takeaways

• Patent expiration and generic entry have significantly reduced LESCOL's revenue potential.
• The global statin market sustains growth but increasingly through generics and newer therapies.
• Strategic growth depends on market expansion, formulation innovation, or combination therapies.
• Present valuation models must incorporate declining brand revenues and the competitive pressure from generics.
• Emerging markets offer opportunities but require tailored regulatory and pricing strategies.

---

FAQs

1. When did the patent for LESCOL expire in major markets?
Patent expiration occurred around 2018 in the US and between 2017-2019 in Europe.

2. How does the price of generic fluvastatin compare to the branded version?
Generic prices are approximately 10% of the branded list price, around $0.10 per pill compared to over $1.00.

3. What are the main drivers of future sales for LESCOL?
Market expansion in emerging regions and new formulations or combinations that maintain patent protection.

4. Are there any regulatory hurdles remaining for LESCOL?
Existing regulatory pathways are well established; however, reformulations could require new approvals, and safety updates may impact sales.

5. What other therapeutic options compete with statins like LESCOL?
PCSK9 inhibitors, ezetimibe, and lifestyle modifications are primary alternatives, especially for patients intolerant to statins.

---

References

1. Industry Market Reports, "Global Statin Market," 2023.
2. FDA, "Patent and Exclusivity Data," accessed 2023.
3. IQVIA, "Prescription Trends," 2022.